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Abstract: Diarrhea is a common disorder in preweaned foals, and there are no antisecretory 
antidiarrheals currently available. The objective of this study was to evaluate the safety and efficacy of 
an enteric-coated paste formulation of a standardized botanical extract of the latex of Croton lechleri 
(SB-300) for the treatment of watery diarrhea in foals. This was a randomized blinded multisite, safety 
and efficacy pilot study of the formulation in client-owned foals with watery diarrhea. Sixty-one foals 
under 16 weeks of age with watery diarrhea were randomly divided into two treatment groups and 
one placebo group, approximately 20 foals each. Each foal received either placebo or investigational 
product/probiotic combination, four times daily. No significant safety issues were noted but the 
transient production of hard feces that was noticed in foals that continued therapy beyond clinical 
improvement. A treatment responder was any foal who developed formed stool (fecal score <3), and 
maintained formed stool for a minimum of 16 consecutive hours within a 24 h period. Statistically 
significant differences in treatment response were demonstrated at a number of time points between 
the investigational product treatment and placebo groups. We conclude that a paste formulation of 
SB-300, a standarized botanical extract of the latex of Croton lechleri, when combined with probiotics, 
is effective in the treatment of watery diarrhea in foals less than 16 weeks of age and warrants further 
investigation without the addition of probiotics. 
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Resumen: La diarrea es un desorden común en potrillos lactantes, y no se dispone de antidiarreicos 
antisecretorios específicos. El objetivo del estudio fue evaluar la seguridad y eficacia de una 
formulación en pasta con cubierta entérica del extracto botánico estandarizado del látex de Croton 
lechleri (SB-300, producto en investigación), para el tratamiento de diarrea acuosa en potrillos. Fue 
un estudio piloto, ciego, aleatorizado, realizado en distintos sitios, en potrillos de clientes particulares 
con diarrea acuosa. Sesenta y un potrillos con diarrea acuosa menores a 16 semanas de edad fueron 
divididos aleatoriamente en dos grupos de tratamiento y uno de placebo, aproximadamente 20 en 
cada grupo. Cada potrillo recibió placebo o la combinación del producto en investigación y probiótico 
cuatro veces al día. No se presentaron problemas de seguridad significativos, pero se observó la 
producción transitoria de heces duras en los que continuaron la terapia luego de la resolución de la 
diarrea. La respuesta al tratamiento fue considerada en aquellos potrillos que desarrollaron heces 
formadas (score fecal <3) y mantuvieron las heces formadas durante un mínimo de 16 h consecutivas 
dentro de un período de 24 h. Se demostraron diferencias estadísticamente significativas en la 
respuesta al tratamiento en distintos tiempos entre los grupos que recibieron el producto y los 
que recibieron placebo. La conclusión fue que la formulación en pasta de (SB-300), un extracto 
botánico estandarizado del látex de Croton lechleri, combinado con probióticos, es efectivo para el 
tratamiento de diarrea acuosa en potrillos menores de 16 semanas de edad y requiere investigaciones 
complementarias sin la adición del probiótico.
Palabras clave: diarrea, potrillo, Croton lechleri, SB 300, canales de cloro
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Introduction
 Diarrhea in foals is very common and there 
are many causative agents (viral, bacterial, protozoa, 
parasites, drug or dietary associated, toxins) that ma-
nifest with clinical signs of watery diarrhea (Atherton 
et al., 2009a, 2009b; Lester, 2001; Wohlfender et al., 
2009). An intestinal insult (virus, bacteria, toxin) results 
in stimulation of intracellular cyclic adenosine mono-
phosphate (cAMP), cyclic guanosine monophosphate 
(cGMP), and cytosolic calcium and/or protein kinases, 
which in turn cause an increase in chloride secretion 
through activation of the cystic fibrosis transmembra-
ne conductance regulator (CFTR) chloride channel 
located on the apical membrane of enterocytes (Ba-
rrett & Keely, 2000) (Figure 1). Other apical channels 
such as calcium-activated chloride channels (CaCCs) 
and type-2 chloride channels also produce intestinal 
chloride secretion. CaCCs appear to play a role in 
the complex etiology of secretory diarrhea caused by 
rotavirus (Lorrot & Vasseur, 2007). Activation of the 
chloride channels and resultant increased secretion 
of chloride into the intestinal lumen results in osmotic 
movement of water into the lumen. This increase in 
intestinal water overwhelms the absorptive capacity 
of the small and large intestine with resultant diarrhea 
(Cottreau et al., 2012). 
Latex of the Croton lechleri tree, (Dragon’s 
blood), which is found in the western Amazonian region 
of South America (Jones, 2003), has been used by 
indigenous tribes as a remedy for diarrhea for many 
years (Mark et al., 2000). Botanical extracts of this latex 
have been shown in vitro to be effective inhibitors of 
both CFTR and CaCCs channels (Fisher et al., 2004). 
This mode of action suggests that it may be an aid in 
reducing the water content of feces during episodes 
of secretory diarrhea.
Specific treatments for diarrhea in foals are ai-
med at causative agents and include the administration 
of antimicrobials; while supportive care may include 
fluid therapy and anti-inflammatories combined with 
antidiarrheal products. Current antidiarrheal treatments 
have a variety of actions including adsorbents, probio-
tics and toxin binders. 
Bismuth subsalicylate has been shown to have 
some antisecretory effects but the exact mode of ac-
tion is unknown (DuPont, 1987; Ericsson et al., 1990). 
Currently there are no products available for foals 
with specific antisecretory properties to normalize the 
intestinal secretion of chloride.
The rationale for this study was that if intestinal 
secretion of chloride in response to an insult can be 
controlled or normalized, then the feces produced 
would have a lower water content which would in turn 
aid in avoiding diarrhea associated dehydration and 
secondary complications associated with it.
Materials and methods
This was a randomized, blinded, multisite, safety 
and efficacy pilot study of enteric-coated SB-300 paste 
in client-owned foals with active watery diarrhea. This 
study was performed in the province of Buenos Aires, 
Argentina, during the 2015 breeding season. Five sites 
were initiated. Site and treatment by site interaction 
terms were included in the models.
Foals
Following identification of potential participants 
and the signing of an informed consent form, screening 
assessments were performed to determine eligibility 
for enrollment into the study. Inclusion criteria were: 
male or female foals of any breed between birth and 
16 weeks of age with a baseline fecal score of 3 or 4 
(Table 1). Foals of foal heat diarrhea age (6-15 days) 
were only considered for enrollment if they showed 
signs of complication of the foal heat diarrhea (fever, 
absence of nursing or other clinical signs such as de-
hydration). Foals were excluded if they were suffering 
from nongastrointestinal disease or injury, fractious, 
moribund, >16 weeks of age, weaned, orphaned, 
treated with oral antidiarrheals within 7 days of the first 
dose administration or had a fecal score of <3 or >4.
Following enrollment foals were randomly 
Figure 1. Mechanisms involved in intestinal epithelial 
cell chloride secretion.SB-300, a botanical extract of 
Croton lechleri (blue circles) binds to the apical surfa-
ce of the cystic fibrosis transmembrane conductance 
regulator and the calcium-activated chloride channels, 
blocking secretion of chloride into the intestinal lumen.
Ca2+: calcium; CACC: calcium-activated chloride chan-
nels; cAMP: cyclic adenosine monophosphate; CFTR: 
cystic fibrosis transmembrane conductance regulator; 
Cl-: chloride; H2O: water; K
+: potassium; Na+: sodium; 
NKCC: sodium-potassium-chloride-cotransporter.
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divided into one of three groups. A randomization 
schedule was generated using SAS proc plan (SAS 
for Windows, version 9.3 or higher, Cary, NC). Medical 
history was obtained and a complete physical exami-
nation was performed on all eligible foals. Baseline 
blood work and fecal analyses were performed. Blood 
work consisted of white blood cell differential percen-
tages and absolute counts, hematocrit and a serum 
biochemistry profile (albumin, alkaline phosphatase 
(ALP), aspartate aminotransferase (AST), albumin/
globulin ratio, calcium, chloride, creatinine, direct bi-
lirubin, gamma glutamyltransferase (GGT), globulin, 
glucose, iron, potassium, sodium, total bilirubin, total 
protein, triglycerides, urea nitrogen, serum amyloid A 
and plasma fibrinogen.
Fecal collection for analyses was conducted 
at baseline only, except for Salmonella spp. cultures 
which were conducted at baseline, 24 and 48 hours 
(+/- 6) hours post t=0 (time of first treatment adminis-
tration). Rotavirus antigen test and clostridial antigen/
toxin ELISA tests were also conducted. Fecal aerobic 
cultures for detection of other pathogens were also 
performed. Additional blood samples were collected 
and analyzed at the end of the treatment period (T72 
h) and at the end of the observation period (T144 h) 
and at post-treatment observation period (72-144 h). 
Following enrollment, the foal entered the treatment 
period (0-72 h), which was followed by a post-treatment 
observation period (72-144 h). From the onset of the 
treatment period to the end of the observation period, 
ongoing fecal scoring (four times daily), clinical as-
sessments including adverse events (four times daily), 
and concomitant medications were recorded. Clinical 
assessments were made based on a standardized 
form with heart rate, respiratory rate, mucous mem-
brane color, capillary in refill time, rectal temperature 
and body condition score being recorded. Total time on 
study for each foal was 6 days. Fecal scoring was con-
ducted jointly with the dosing times (four times a day 
with a minimum of 4 hours in between assessments) 
during the treatment period, followed by twice a day 
thereafter until the end of the observation period.
Treatments
The study design included 3 treatment groups. 
Treatment groups were divided such that approxima-
tely 20 foals each would receive: investigational pro-
duct/probiotic (IVP/P) four times daily (QID) (Group 1), 
IVP/P two times daily (BID) and placebo BID (Group 2), 
or placebo QID (Group 3). Group 2 therefore received 
alternating doses of IVP/P and placebo that represents 
half the daily dose of IVP/P received by Group 1. Each 
foal received a 30 ml syringe of either IVP or placebo 
QID. There were two test materials: one contained 
the IVP and a probiotic (DigestivTM), the second was 
a placebo.
Both test materials were formulated as a paste 
and packaged in identical 30 ml metered syringes. Both 
test materials contained the same excipients. The IVP 
(SB-300) is a proprietary standardized botanical extract 
of sustainably harvested Croton lechleri. All formulation 
components were considered safe for use in animals.
The following medications were prohibited 
beginning at baseline through to the end of the obser-
vation period: additional probiotics, oral electrolytes 
(IV fluids were allowed) and other oral antidiarrheal 
treatments (within 7 days prior to the first dose being 
administered and while on study).
The weight range for foals enrolled in the study 
was 37-140 kg, which resulted in a dosing range of 
2-18 mg/kg.
Descriptive statistics (number of subjects, mean, 
standard deviation, standard error of the mean, me-
dian, minimum and maximum values) were presented 
for age (weeks), baseline body weight (kg) and base-
line fecal score, in each treatment group.
Safety was assessed by the following parame-
ters: adverse events, plasma chemistry and hematolo-
gy. Descriptive statistics were presented by treatment 
group, for each parameter for the screening visit, end 
of treatment period, end of observation period and 
for the changes from screening to end of treatment 
period and end of observation period. Possible diffe-
rences between treatment groups in the changes from 
screening were assessed by ANCOVA modeling. The 
model contained baseline fecal score as a covariate 
with treatment, time point and treatment by time point 
as a fixed effect. Residuals from the model were inves-
tigated for normality using the Shapiro-Wilk test. If the 
normality assumption was rejected at an alpha level 
of 0.05, the degree of departure from normality was 
Table 1. Fecal score. Foals with a fecal score of 3 or 
4 were eligible for enrollment. Foals with a fecal score 
of 1 or 2 were considered to have insufficient diarrhea 
for enrollment and those with a grade 5 were excluded 
due to the possibility of hemorrhagic enterocolitis. 
Fecal description Score
Well-formed feces  1
Soft or very soft, moist (cow patty consis-
tency)
2
Watery, liquid feces with some particulate 
matter either evident adhered to the tail or 
perineum or upon the surface of the bedding
3
Severe watery diarrhea with no particulate 
matter visible or no diarrhea seen but watery 
staining of the tail, perineum or walls evident.
4
Hemorrhagic diarrea 5
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investigated and a rank transformation was applied. 
Additionally, clinically significant changes from scree-
ning were investigated for white blood cell count (chan-
ge from screening >12,500 cells/μl), serum amyloid A 
(change from screening >30 μg/ml) and percentage 
of banded neutrophils (change from screening >5 
%). The number (%) of foals with clinically significant 
changes was presented by treatment group. Possible 
differences between treatment groups were assessed 
with Fisher’s Exact (2-tail) test.
To standardize care and where possible any 
foal that received antibiotics was placed on ceftio-
fur (5 mg/kg q8h) and amikacin (22 mg/kg q24h). A 
treatment responder was defined as a foal that deve-
loped formed feces or had no feces (fecal score <3), 
and maintained formed feces or no feces (i.e. no fecal 
score of 3, 4 or 5) for a minimum of 16 consecutive 
hours within a 24 hours period during the 72 hours 
treatment period. However, due to the difficulty in 
determining if “no observed feces” actually correspon-
ded to “no feces”, only those foals with observable 
feces that could be scored as <3 were considered to 
be responders.
All tests of significance were assessed at alpha 
= 0.05, 2-sided. No adjustments were applied for 
multiple comparisons. All statistical analyses were 
conducted using SAS for Windows.
For the treatment responder parameters, the 
number (%) of successes was presented for each 
treatment group. Possible differences between 
treatment groups were assessed using a generalized 
linear mixed model assuming a binomial distribution 
and a logit link. The model contained baseline fecal 
score as a covariate with treatment, time and treatment 
by time interaction as fixed effects.
Subgroup analyses, including only those foals 
with a baseline fecal score of 4 were also completed.
Results
 At study completion site 1 through 5 had enro-
lled 22, 6, 21, 6 and 6 foals respectively, resulting in a 
total of 61 enrolled foals. One foal was the subject of 
an early withdrawal due to debilitation and worsening 
clinical condition, with a total of 60 foals completing 
the study. Data from all foals were used in the analysis 
of safety. The safety population included all animals 
that received at least one dose of IVP or placebo. The 
safety population included 20 animals treated with the 
IVP QID, 21 animals treated with IVP BID and placebo 
BID, and 20 animals treated with placebo QID. An effi-
cacy population was defined as a subset of the safety 
population excluding 6 foals that had ≤ 1 recorded fecal 
score through the 144 hours of the study. The efficacy 
population included 19 animals treated with IVP QID, 
19 animals treated with IVP BID and placebo BID and 
17 animals treated with placebo QID.
An arbitrary scoring system was established 
with “no observation of feces” being noted as just 
that. In the 0-72 h time frame, there were a total of 
732 possible fecal scores with 496 recorded as "No 
fecal sample (NFS)". For each treatment group, the 
following scores were recorded as NFS: IVP/P QID 
(161 of 240), IVP/P BID/placebo BID (171 of 252), and 
placebo QID (164 of 240).
Age, body weight and baseline fecal score were 
similar among treatment groups for both the safety and 
efficacy populations. The chi-square p-value was not 
statistically different between the groups for those that 
received antibiotics, indicating a similar distribution.
Safety parameters
Hematology and serum amyloid A (SAA). The 
comparison of the number of foals with clinically signifi-
cant white blood cell count and serum amyloid A values 
were not found to be statistically different between 
groups at enrollment or by responder/nonresponder.
Serum biochemistry. No clinically significant 
differences were found at screening or between 
treatment/placebo groups at T 72 h or T 144 h.
Adverse events
An adverse event was defined as any change 
in physical of clinical pathology evaluations from ba-
seline. These were classified as mild, moderate or 
severe. Adverse events noted included alopecia of 
the perineal area, fevers and increases/decreases in 
white cell counts. Most adverse events noted were 
deemed to be related to the underlying disease/dia-
rrhea rather than having a direct relationship with the 
investigational product other than the development of 
transient hard feces, which was noted in a number of 
foals. No severe events were reported during either 
the treatment or observation period.
Treatment outcome parameters and analyses
The number of responders in each group and 
statistical comparisons for the evaluated population are 
presented in Table 2. The percentage of responder from 
0-72 h was greater in the IVP BID group (68 %) than in 
the placebo group (35 %) (p= 0.03). The percentage of 
responders from 0-96 h was also found to be greater in 
IVP BID group (79 %) when compared to the placebo 
group (47 %) (p= 0.03). From 0-120 h, the percentage of 
responders in the IVP QID group was 84 % versus 53 % 
in the placebo group, which was found to be significant 
(p= 0.04). No significant differences were found between 
groups for the periods 0-24 h and 0-48 h.
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For the subset of foals with a baseline fecal sco-
re of 4, the percentage of responders from 0-96 hours 
was found to be significantly different (p= 0.02) bet-
ween the IVP BID (85 %) and placebo groups (39 %). 
For the interval from 0-120 hours, the IVP QID group 
was found to be significantly different (p= 0.02) from 
the placebo group (94 % versus 46 %, respectively; 
Table 3). No significant differences were found for the 
periods 0-24 h, 0-48 h and 0-72 h. 
Discussion
 This trial design allowed for 72 hours of 
treatment and a further 72 hours observation period. 
This was designed to allow extended assessments 
of foals post-treatment, as the duration of an acute 
diarrhea episode in foals is commonly 5-6 days. A key 
component and often, key difficulty in any diarrhea 
study, is the ability to evaluate fecal production. The 
diarrhea scoring system used in this trial was derived 
from a scoring system that had been used in a pre-
vious safety study for the same product carried out in a 
group of older foals (Divers; personal communication). 
Extensive literature searches revealed little in terms of 
scoring fecal production in horses or foals. The most 
common difficulties encountered and not adequately 
addressed by this scoring system are the following: 
1. No obvious fecal production due to the feces 
simply not being observed and thereafter mixed with 
bedding or the fecal production is of such watery con-
sistency that if not directly observed it soaks directly 
through the bedding, 
2. No fecal production associated with ileus in 
the acute phase of illness, and 
3. No fecal production, which frequently occurs 
in the recovery phase. 
While in each of these scenarios we may expect 
to find some other clinical indicators such as improve-
ment in attitude and appetite that may indicate if the 
Table 2. Number and percentage of responders (a foal that developed formed feces -fecal score < 3-, and 
maintained formed feces for a minimum of 16 consecutive hours within a 24 hours period during the 72 hours 
treatment period), during the treatment and observation periods. Also, statistical comparison of each treatment 
group to the placebo.
Pairwise comparison to placebo 
Fisher’s Exact (2-tail) p-value
Period Active QID Active BID Placebo QID Active QID Active BID
Neo 101 Neo 101 Neo 101 Neo 101 Neo 101
0-24 h   0/19   (0.0 %)   2/19  (10.5 %) 3/17 (17.6 %) 0.96 0.46
0-48 h   2/19 (10.5 %)   6/19  (31.6 %) 3/17 (17.6 %) 0.55 0.21
0-72 h   9/19  (47.4 %) 13/19 (68.4 %) 6/17 (35.3 %) 0.40 0.03
0-96 h 13/19  (68.4 %)  15/19 (78.9 %) 8/17 (47.1 %) 0.20 0.03
0-120 h 16/19  (84.2 %)  14/19 (73.7 %) 9/17 (52.9 %) 0.04 0.10
0-144 h 17/19 (89.5 %) 15/19 (78.9 %) 10/17 (58.8 %) 0.04 0.17
Table 3. Number and percentage of responders of the subset of foals that had a fecal score of 4 upon enroll-
ment, during the treatment and observation periods and shows statistical comparison of each treatment group 
to the placebo.
Pairwise comparison to placebo 
Fisher’s Exact (2-tail) p-value
Period Active QID Active BID Placebo QID Active QID Active BID
 0-24 h   0/16  (0.0 %)   1/11    (9.1 %) 0/13    (0.0 %) 0.99 0.98
 0-48 h   2/16 (12.5 %)   3/12  (25.0 %) 1/13    (7.7 %) 0.78 0.22
 0-72 h   8/16 (50.0 %)   9/13  (69.2 %) 4/13  (30.8 %) 0.31 0.05
 0-96 h 12/16 (75.0 %) 11/13  (84.6 %) 5/13  (38.5 %) 0.05 0.02
 0-120 h 15/16 (93.8 %) 10/13  (76.9 %) 6/13  (46.2 %) 0.02 0.10
 0-144 h 15/16 (93.8 %) 11/13  (84.6 %) 7/13  (53.8 %) 0.03 0.10
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animal is improving it was felt that many of these indica-
tors are subjective and frequent exceptions were likely. 
Given the strict use of the term “NFS” for any 
period when no fecal production was witnessed, many 
foals had missing fecal scores, which resulted in 6 foals 
being excluded from the efficacy analysis due to only 
having a single fecal score. Therefore, it is possible 
that these foals responded or reached clinical reso-
lution before such time as was recorded for them. A 
recommendation for future studies would be the use of 
cameras with recording systems in the stalls to facilitate 
detection of defecation.
The product was palatable and easily adminis-
tered in the paste formulation. There were no signifi-
cant safety issues related to administration. One foal 
was withdrawn due to a worsening clinical condition. 
The foal had marked signs of sepsis and a cardiac 
arrhythmia was noted at withdrawal that had not been 
present at enrollment. The foal died 18 hours later and 
a necropsy indicated septicemia with cultures yielding 
a Pseudomonas sp. Unblinding of the foal’s treatment 
group was requested at withdrawal and it was revealed 
that the foal had received placebo. It was noted that 
a number of foals in the study produced hard feces, 
which in some cases was noted to have a small amount 
of surface blood, likely related to mucosal bleeding. 
In total, 5 foals were noted to have this change within 
the 144 hours of the study. The production of hard 
feces in all cases was transient and none of the foals 
experienced any long-term medical problems related 
to the production of hard feces. In the opinion of the 
trial veterinarian, the production of hard feces was 
more likely to occur in cases where the diarrhea had 
resolved before the end of the treatment period but 
use of the product was continued past the resolution 
of the diarrhea.
Analysis of plasma biochemistry and hemato-
logy revealed that foals across the three groups had 
similar laboratory results on admission indicating a 
similar level of systemic illness across the groups. 
Through the regulation of chloride channels, SB-300 
prevents hyper-stimulation of electrolyte secretion in 
response to an intestinal insult. This helps to control 
fluid balance and prevent dehydration but is not a direct 
treatment for the cause of the diarrhea. Depending on 
the etiology of diarrhea, antibiotics may be required and 
as such where deemed necessary based on clinical 
and laboratory findings foals were placed on antibiotic 
therapy. 
Another challenge when performing trials eva-
luated foals with diarrhea is the range of etiologies 
that may be involved. Diarrhea may be infectious or 
noninfectious and the animals may show minimal cli-
nical signs other than the diarrhea or may be severely 
systemically ill. Standardization of the degree of illness 
and etiology is impossible. Animals may appear to only 
be mildly ill if presented soon after the onset of diarrhea 
and deteriorate after admission or vice versa. All efforts 
were made to try to enroll foals with a comparative level 
of illness. To this effect only foals with diarrhea scores 
of 3 or 4 were enrolled. Foals with lesser scores were 
likely to be not as ill and foals with fecal scores of 5 
frequently carry a poor prognosis which could result 
in a negative bias. Every effort was made not to enroll 
foals with ‘foal heat’ diarrhea which is regarded as 
being a normal physiological event. Foals with foal heat 
diarrhea are normally presented from 6-15 days but 
are bright, actively nursing with no changes in physical 
parameters such as heart rate or body temperature. If 
a foal of that age group was presented with a diarrhea 
score of 3 or 4, it had to demonstrate some indication 
of complication of the foal heat diarrhea such as fever 
to be eligible for enrollment. Comparison of physical 
and laboratory parameters between the treatment 
groups indicated that the animals were similarly ill 
across all groups.
Standardization per etiology is also impossible. 
Definitive determination of the cause of diarrhea is not 
possible in many cases (Savage, 2009; Sellon, 2014). 
In this trial an etiology was determined in 28.4 % of 
cases (Deferrari et al., 2016). An additional complica-
tion is the likely mixed etiology of many cases of foal 
diarrhea and new research indicating the presence 
of previously unrecognized viruses as causes of foal 
diarrhea (Vega et al., 2016).
The argument could be made that administration 
of antibiotics to some foals and not to others could 
impact the outcome and while this is indeed true if 
one treatment group contains a large number of foals 
that receive antibiotics compared to other groups, 
the similar distribution between groups in this trial for 
those that received antibiotics; IVP/P QID 13 of 19, 
IVP/P BID/placebo BID 13 of 19 and placebo QID 9 of 
17, indicates that the likely impact of antibiotics on the 
overall comparative analysis was minimal. Similarly, 
the argument could be made that younger foals may 
have a tendency towards more severe illness than 
older foals. When the responders were divided by 
age group (<1 month and >1 month), there was little 
numerical difference between the responders by age 
group but there was a numerical difference between 
treated and placebo for foals <1 month of age. The 
placebo group of foals >1 month of age only consisted 
of 2 foals and no inferences could be drawn (Table 4).
Probiotics are live organisms that, when ad-
ministered at adequate concentrations, provide a 
beneficial effect beyond that of their nutritional value. 
They are used widely in the treatment of diarrhea in 
humans, small animals and equines. To standardize 
their use across this study, probiotics were included 
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with the investigational product in the dosage syringe. 
The positive or negative effect of the probiotics on the 
outcome of this trial is debatable and unknown. At this 
point in time the only conclusion that can be drawn was 
that the combination of the investigational product with 
probiotics appears to be effective in the treatment of 
foal diarrhea. 
In conclusion, the administration of a paste 
formulation of SB-300 was well tolerated with minimal 
adverse events and showed numerical and statistically 
significant improvement in the resolution of diarrhea 
in nonweaned foals less than 4 months of age. It is 
recommended that a larger trial be performed to further 
evaluate the benefits of the product without additional 
probiotic.
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Neo 101
Placebo
Neo 101
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